Is Insight Molecular Diagnostics Inc. (IMDX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 2.3% / 30% | 5.5% / 30% | 1.0% / 30% | 1984.69% / 5% | ✗ NOT HALAL |
| DJIM | 2.3% / 33% | 5.5% / 33% | 1.0% / 33% | 1984.69% / 5% | ✗ NOT HALAL |
| MSCI | 10.4% / 33% | 24.6% / 33% | 4.6% / 33% | 1984.69% / 5% | ✗ NOT HALAL |
| S&P | 2.3% / 33% | 5.5% / 33% | 1.0% / 33% | 1984.69% / 5% | ✗ NOT HALAL |
| FTSE | 10.4% / 33% | 24.6% / 33% | 4.6% / 50% | 1984.69% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 55.1% | |
| Operating Margin | -2950.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -23603.1% | |
| Return on Assets (ROA) | -28.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$21M |
| Free Cash Flow | -$21M |
| Total Debt | $4M |
| Current Ratio | 2.8 |
| Total Assets | $35M |
Price & Trading
| Last Close | $4.11 |
| 50-Day MA | $5.65 |
| 200-Day MA | $4.66 |
| Avg Volume | 69K |
| Beta | 1.3 |
|
52-Week Range
$2.33
| |
About Insight Molecular Diagnostics Inc. (IMDX)
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers VitaGraft Kidney, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for kidney transplantation; VitaGraft Liver, a blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA for liver transplantation; and GraftAssure, a dd-cfDNA test that uses droplet digital PCR technology to measure the concentration of dd-cfDNA using 48 predefined SNPs. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. Insight Molecular Diagnostics Inc. was formerly known as OncoCyte Corporation and changed its name to Insight Molecular Diagnostics Inc. in June 2025. Insight Molecular Diagnostics Inc. was incorporated in 2009 and is based in Nashville, Tennessee.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Insight Molecular Diagnostics Inc. (IMDX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Insight Molecular Diagnostics Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Insight Molecular Diagnostics Inc.'s debt ratio?
Insight Molecular Diagnostics Inc.'s debt ratio is 2.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 10.4%.
What are Insight Molecular Diagnostics Inc.'s key financial metrics?
Insight Molecular Diagnostics Inc. has a market capitalization of $115M, and revenue of $2M. Return on equity stands at -23603.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.